)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
TScan Therapeutics (TCRX) investor relations material
TScan Therapeutics KOL Event summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOL Event summary8 Dec, 2025
Introduction and agenda
Presented updated data from the ALLOHA phase I study and discussed the market opportunity for TSC-101, a next-generation TCR-T cell therapy for hematologic malignancies.
Outlined plans to launch a pivotal study of TSC-101 in Q2 next year and provided updates on manufacturing and regulatory progress.
Event focused on updated Phase 1 ALLOHA trial data and market opportunity for TSC-101, with presentations on clinical results, manufacturing, pivotal trial design, and commercial strategy.
KOL background and credentials
Dr. Ran Reshef, Director of Translational Research and Blood and Marrow Transplantation at Columbia University, presented updated clinical data.
Stephen Camiolo, SVP of Market Access, has launched multiple cell therapy products, including Yescarta, Tecartus, and Amtagvi.
Presenters included Gavin MacBeath, Ph.D., Ran Reshef, M.D., M.Sc., Stephen Camiolo, BSN, ACNP, and Chrystal Louis, M.D., M.P.H., each contributing expertise in clinical, manufacturing, and market aspects.
Market insights and analysis
TSC-101 integrates seamlessly into existing transplant workflows, minimizing operational complexity.
The eligible U.S. patient population is estimated at 2,100 annually, with peak U.S. revenues projected over $1.4 billion.
Expansion to additional HLA types (TSC-102) could double the global addressable market to 15,000–20,000 patients.
The treatment landscape is highly concentrated, with 40 centers expected to treat two-thirds of eligible U.S. patients.
Allogeneic HCT is the only curative option for AML/MDS, but 38-44% relapse within two years, highlighting a significant unmet need.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next TScan Therapeutics earnings date
Q4 20255 Mar, 2026
Next TScan Therapeutics earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage